A RASopathy gene commonly mutated in cancer: the neurofibromatosis type 1 tumour suppressor

Nancy Ratner,Shyra J. Miller
DOI: https://doi.org/10.1038/nrc3911
IF: 78.5
2015-04-16
Nature Reviews Cancer
Abstract:Key PointsThe neurofibromatosis type 1 (NF1) research community has identified the NF1 gene and has developed mouse models of plexiform neurofibroma, optic pathway glioma, malignant peripheral nerve sheath tumours and juvenile myelomonocytic leukaemia, all of which are tumours that are found in patients with NF1.The NF1 gene encodes a RAS GTPase-activating protein known as neurofibromin and is one of several genes that (when mutant) affect RAS–MAPK signalling, causing related diseases collectively known as RASopathies.Preclinical and clinical testing consortia have found that inhibition of MEK shrinks benign tumours but that combinatorial therapies are likely to be needed for NF1-related malignancies. These may include targeting of other RAS effector pathways. Treatments that target NF1 could also be tested as treatments for other RASopathies.The neurofibromin protein has been studied, and many potential interacting partners have been identified. However, many questions remain concerning the functional importance of possible interaction partners and roles of neurofibromin protein domains, and the interactions between neurofibromin and cyclic AMP signalling pathways.NF1 mutations are common in most sporadic tumour types and can mediate resistance to therapy.
oncology
What problem does this paper attempt to address?